Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.83 +8.0%	$1.90	$1.29 ▼ $13.07	$68.57M	-0.13	1.16 million shs	893,086 shs
INCR InterCure	$1.49 -0.7%	$1.53	$1.17 ▼ $2.62	$67.90M	1.18	26,011 shs	8,753 shs
LPCN Lipocine	$3.13 +0.6%	$3.31	$2.68 ▼ $7.90	$16.75M	1.3	32,896 shs	15,886 shs
PYXS Pyxis Oncology	$1.14 -0.4%	$1.19	$0.83 ▼ $5.39	$70.31M	1.13	731,766 shs	83,630 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	+2.18%	-6.11%	-32.13%	-1.17%	-60.05%
INCR InterCure	+1.01%	+2.04%	0.00%	+13.64%	-34.78%
LPCN Lipocine	-4.89%	-1.58%	-0.96%	+9.89%	-57.34%
PYXS Pyxis Oncology	+2.24%	+3.64%	-15.56%	+29.94%	-60.69%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	2.5344 of 5 stars	3.6	1.0	0.0	0.0	2.5	2.5	0.6
INCR InterCure	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	1.5505 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.0	0.6
PYXS Pyxis Oncology	1.2081 of 5 stars	3.4	1.0	0.0	0.0	0.0	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.18	Buy	$21.40	1,072.60% Upside
INCR InterCure	0.00	N/A	N/A	N/A
LPCN Lipocine	3.00	Buy	$9.00	187.54% Upside
PYXS Pyxis Oncology	2.80	Moderate Buy	$9.00	692.95% Upside

Current Analyst Ratings Breakdown

Latest LPCN, PYXS, BMEA, and INCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/27/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/10/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/29/2025	LPCN Lipocine	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$8.00
5/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
5/15/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/6/2025	BMEA Biomea Fusion	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$40.00 ➝ $18.00
5/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$1.42 per share	N/A
INCR InterCure	$238.85M	0.28	N/A	N/A	$2.36 per share	0.63
LPCN Lipocine	$3.67M	4.56	N/A	N/A	$3.93 per share	0.80
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	$2.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.55	N/A	N/A	N/A	N/A	-197.71%	-134.84%	7/30/2025 (Estimated)
INCR InterCure	-$18.32M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)
LPCN Lipocine	$10K	-$1.02	N/A	∞	N/A	N/A	-26.68%	-24.77%	8/6/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.59	N/A	N/A	N/A	N/A	-57.49%	-45.17%	8/13/2025 (Estimated)

Latest LPCN, PYXS, BMEA, and INCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
7/30/2025	Q2 2025	BMEA Biomea Fusion	-$0.64	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	PYXS Pyxis Oncology	-$0.29	-$0.35	-$0.06	-$0.35	N/A	N/A
5/8/2025	Q4 2024	LPCN Lipocine	-$0.35	-$0.35	N/A	-$0.35	$0.35 million	$0.09 million
5/5/2025	Q1 2025	BMEA Biomea Fusion	-$0.84	-$0.80	+$0.04	-$0.80	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
LPCN Lipocine	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	2.25	2.25
INCR InterCure	0.34	1.73	1.18
LPCN Lipocine	N/A	15.64	15.64
PYXS Pyxis Oncology	N/A	7.75	7.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
INCR InterCure	8.34%
LPCN Lipocine	9.11%
PYXS Pyxis Oncology	39.09%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
INCR InterCure	0.24%
LPCN Lipocine	6.35%
PYXS Pyxis Oncology	10.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	37.57 million	30.65 million	Optionable
INCR InterCure	350	45.57 million	N/A	Optionable
LPCN Lipocine	10	5.35 million	5.01 million	No Data
PYXS Pyxis Oncology	60	61.95 million	55.38 million	Optionable

LPCN, PYXS, BMEA, and INCR Headlines

Recent News About These Companies

Pyxis Oncology Inc News (PYXS) - Investing.com

4 hours ago | investing.com

Pyxis Oncology (NASDAQ:PYXS) Stock Price Up 3.6% - Time to Buy?

July 8 at 3:33 AM | marketbeat.com

Pyxis Oncology Chief Financial, Operating Officer Pamela Connealy Retires >PYXS

July 3, 2025 | marketwatch.com

Pyxis Oncology Appoints New Principal Financial Officer

July 3, 2025 | tipranks.com

Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 30, 2025 | globenewswire.com

Pyxis Oncology Insiders Lose Out As Stock Sinks To US$1.14

June 19, 2025 | finance.yahoo.com

Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Average Rating of "Moderate Buy" from Brokerages

June 16, 2025 | marketbeat.com

Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments

May 30, 2025 | tipranks.com

Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Globus Medical (GMED) and Ramsay Health Care (OtherRMSYF)

May 22, 2025 | theglobeandmail.com

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025 | globenewswire.com

Pyxis Oncology to Participate in Two Upcoming Investor Conferences

May 14, 2025 | globenewswire.com

New Approaches to Tumor Targeting Are Driving the Next Wave of Oncology Breakthroughs

May 8, 2025 | baystreet.ca

Pyxis Oncology reveals promising preclinical data for cancer drug

April 27, 2025 | investing.com

Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

April 25, 2025 | globenewswire.com

5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms

April 23, 2025 | zacks.com

Top Cancer Stocks to Buy to Boost Your Portfolio's Health

April 16, 2025 | zacks.com

Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

April 2, 2025 | globenewswire.com

Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025

March 25, 2025 | globenewswire.com

Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)

March 24, 2025 | markets.businessinsider.com

RBC Capital Remains a Buy on Pyxis Oncology (PYXS)

March 20, 2025 | markets.businessinsider.com

Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)

March 18, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN, PYXS, BMEA, and INCR Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.82 +0.14 (+7.99%)

As of 12:35 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

InterCure NASDAQ:INCR

$1.49 -0.01 (-0.67%)

As of 12:20 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Lipocine NASDAQ:LPCN

$3.13 +0.02 (+0.64%)

As of 12:37 PM Eastern

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

Pyxis Oncology NASDAQ:PYXS

$1.14 -0.01 (-0.44%)

As of 12:41 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time